Symptomatic intraocular pressure dysregulation during clopidogrel exposure after patent foramen ovale closure in a patient with ocular hypertension and angle crowding: a Case Report - Summary - MDSpire
Advertisement
Intraocular Pressure Dysregulation Symptoms Associated with Clopidogrel Treatment Following Patent Foramen Ovale Closure in a Patient with Ocular Hypertension and Angle Crowding: A Case Study
To report a case of intraocular pressure (IOP) dysregulation symptoms associated with clopidogrel treatment following percutaneous patent foramen ovale closure.
Approach:
Patient Case Description: A 52-year-old woman with ocular hypertension and angle crowding developed ocular discomfort, eye pain, and blurred vision after clopidogrel exposure following percutaneous patent foramen ovale closure.
Monitoring and Assessment: 24-hour IOP monitoring showed significant peak elevation and diurnal fluctuation during symptomatic exposure to clopidogrel, indicating potential IOP dysregulation.
Key Findings:
The patient experienced recurrent ocular symptoms after clopidogrel administration, which improved upon withdrawal.
24-hour IOP monitoring revealed marked peak IOP elevation and fluctuations during symptomatic phases, but baseline 24-hour IOP monitoring was not performed, limiting comparative analysis.
Interpretation:
The case presents a temporal association between clopidogrel exposure and IOP dysregulation symptoms, but definitive evidence of a drug-induced effect is lacking due to missing baseline assessments.
Limitations:
Formal gonioscopy and symptomatic-phase angle reassessment were not performed, which limits the understanding of angle status during symptoms.
Baseline 24-hour IOP monitoring was not conducted, limiting the ability to confirm worsening relative to the patient's baseline diurnal pattern.
Conclusion:
This case highlights the potential for non-hemorrhagic ocular adverse events associated with clopidogrel, particularly in patients with pre-existing ocular conditions.
In a panel at the Retina Innovation Summit in Montreal, regulatory experts, drug developers, academic advisors, and investors discussed how evolving FDA guidance is reshaping the path from clinical trials to approval.
